MDOH
Discover related
2 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
| TripSit | PiHKAL | ||
|---|---|---|---|
| Classification | |||
| Class / category | — | ||
| Also known as | — | N-HYDROXY-MDA3,4-METHYLENEDIOXY-N-HYDROXYAMPHETAMINE | |
| Safety | |||
| Dose · Oral | |||
| Threshold | 80 mg | — | |
| Light | 100–120 mg | — | |
| Common | 120–150 mg | 100–160 mg | ≠ |
| Heavy | 150 mg+ | — | |
| Duration | |||
| Onset | 20–40 minutes | — | |
| Total | 4–6 hours | 3–6 hours | ≠ |
| After-effects | 1–6 hours | — | |
Dose at a glance
Each database's primary-route ladder on one shared scale — see where ranges line up or shift.
Duration at a glance
Total duration on one shared scale.
TripSit summary
An entactogen, stimulant and psychedelic first synthesised by Alexander Shulgin, MDOH is an analogue of MDA. Described as highly psychedelic, it is likely a serotonin releasing agent. It has not seen widespread use, perhaps due to a number of reported negative side effects such as urinary retention and a heavy comedown.
PiHKAL summary
An N-hydroxy relative of MDA whose effects and effective dose turned out to be nearly identical to those of MDA itself. This raised the intriguing possibility that the two compounds interconvert in the body, though human metabolic studies remain undone.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.